Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.
Castagna L
Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015015. doi: 10.4084/MJHID.2015.015
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.
Pierdominici M
FASEB J. 2013 Nov 6;28(2):524-35. doi: 10.1096/fj.13-235655
Targeting TRAIL agonistic receptors for cancer therapy.
Carlo-Stella C
Clin Cancer Res. 13(8):2313-7.
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma.
Ruffini PA
Curr Gene Ther. 5(5):511-21.
Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.
Siena S
J Clin Oncol. 18(6):1360-77.
Cell therapy: achievements and perspectives.
Bordignon C
Haematologica. 84(12):1110-49.
Ex vivo expansion of hematopoietic cells and their clinical use.
Aglietta M
Haematologica. 83(9):824-48.
Stem cell manipulation: why and how performing peripheral blood progenitor cell purging.
Rizzoli V, Carlo-Stella C
Crit Rev Oncol Hematol. 26(2):101-15.
Stem cells and stem cell transplantation.
Carlo-Stella C, Tabilio A
Haematologica. 81(6):573-87.
Stem cell purging: an intriguing dilemma.
Rizzoli V, Carlo-Stella C
Exp Hematol. 23(4):296-302.